FB-825 is under clinical development by Oneness Biotech and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect FB-825’s likelihood of approval (LoA) and phase transition for Allergic Rhinitis took place on 16 Feb 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their FB-825 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
FB-825 is under development for the treatment of allergic asthma, atopic dermatitis, allergic rhinitis, food alleryg and hyperimmunoglobulin E syndrome. It is administered through intravenous route. FB-825 is a humanized monoclonal antibody that targets to the specific CemX domain and kills the membrane IgE positive B lymphocytes. It is administered by intravenous route.
Oneness Biotech overview
Oneness Biotech is a biopharmaceutical company. The company’s product pipeline comprises ON101 against diabetic foot ulcer, FB825 for atopic dermatitis, allergic asthma, FB704A against severe asthma, OB318 against cancer and FB918 against asthma. It offers products in the therapeutic areas of dermatology, immunology and infectious diseases. Oneness Biotech is headquartered in Taipei, Taiwan.
Quick View FB-825 LOA Data
|Highest Development Stage|